Prostaglandin analogue and beta-adrenergic receptor blocker

This page covers all Prostaglandin analogue and beta-adrenergic receptor blocker drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Beta-adrenergic receptor.

Targets

Beta-adrenergic receptor

Phase 3 pipeline (1)

• unfixed Latanoprost and Timolol · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Ophthalmology
  Latanoprost is a prostaglandin analogue that reduces intraocular pressure by increasing uveoscleral outflow, while Timolol is a beta-adrenergic receptor blocker that reduces intraocular pressure by decreasing aqueous humor production.

Patent intelligence

• prostaglandin analogue and beta adrenergic receptor blocker patent landscape — aggregated cliff calendar, attackable patents, originator estates